Tallas Biotech Inc.

What Tallas Biotech Inc. does

Tallas Biotech Inc. is a pre-clinical biopharmaceutical company founded in 2019 and headquartered in New York. It operates a single-platform strategy centered on its proprietary RNAccelerate platform, which combines AI algorithms with laboratory research to discover RNAi-based therapeutics targeting disease-causing genome sequences previously considered 'undruggable.' The scientific approach leverages the RNA interference (RNAi) mechanism, in which RNAi binds complementary mRNA via the RISC complex to cleave the target and inhibit protein synthesis.

The company's wholly owned pipeline currently consists of two programs: Hereditary Hemochromatosis, a rare disease indication in the discovery stage, and Pancreatic Cancer, which has been advanced to the pre-clinical stage. Both programs target indications with significant unmet medical need, and the company emphasizes its platform's potential to reduce failure rates and lower discovery costs compared with conventional approaches.

Tallas Biotech is pre-revenue and has no disclosed customers, licensing agreements, or institutional funding. Its intended go-to-market approach is partnership-led, targeting larger pharmaceutical and biotechnology companies for licensing or co-development of its pipeline candidates. With a team of 1-10 employees led by co-founder and CEO Ali Shah, the company relies on a lean operating model and digital channels (LinkedIn, X, Facebook) for industry visibility. The absence of disclosed patents, partnerships, or capital raises represents a material information gap for investors evaluating the company's commercial readiness.

Name

Tallas Biotech Inc.

Legal name

Tallas Biotech

Website

https://tallas.io

Company type

Private

Founded year

2019

Operating status

Operating

Headcount range

1–10 employees

Short description

Tallas Biotech Inc. is a pre-clinical biopharmaceutical company developing RNAi-based therapeutics through its AI-powered RNAccelerate platform, targeting rare diseases and oncology indications including Hereditary Hemochromatosis and Pancreatic Cancer. It intends to monetize via pharmaceutical licensing and co-development partnerships.

Ownership category

akta.pro rank

Product category

Biopharmaceutical R&D / RNAi Drug Discovery

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

RNA Therapeutics Platforms & Design (sequence design, target ID/validation, AI/bioinformatics) (HLAAADAG)

akta.pro secondary industry

siRNA Therapeutics (gene silencing) (HLAAADAB)

Keywords

• RNAi therapeutics
• Drug discovery platform
• Rare disease treatments
• Oncology drug development
• AI-driven biotech

Headquarters

HQ city

New York

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Services

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

1. Drug Development and Licensing: Pre-revenue biotech company focused on developing RNAi-based therapeutics through their RNAccelerate platform. Revenue generation expected through licensing deals, partnerships with pharmaceutical companies, or eventual product commercialization upon successful clinical development.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

Tallas Biotech operates an AI-powered drug discovery platform called RNAccelerate that uses RNA interference (RNAi) editing technology to target disease-causing genome sequences. The company is developing a wholly-owned pipeline of RNAi-based therapeutics, with current programs in Hereditary Hemochromatosis (Discovery phase) and Pancreatic Cancer (Pre-Clinical phase). The company's mission is to enable the next wave of RNAi drugs that address previously 'undruggable' conditions in rare diseases and oncology.

Product overview

Tallas Biotech is a biopharmaceutical company focused on drug discovery using its proprietary RNAccelerate platform, which employs RNAi (RNA interference) editing technology to isolate and target disease-causing genome sequences. The company operates as a single-platform strategy company, with the RNAccelerate platform serving as the core technology for all pipeline programs.

Differentiator

Problem solved

Functional benefit

Products and services

• RNAccelerate Platform

Segments3 records

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature2 records

Scale indicators2 records

Recent moves4 records

Expansion highlights4 records

Emerging players

• Ascidian Therapeutics: Clinical-stage RNA editing company developing therapeutics for neurological and rare diseases. Comparable as an early-stage RNA-modality company targeting genetic disease with a platform approach, similar to Tallas's discovery-stage posture.
• Atalanta Therapeutics: Emerging RNAi therapeutics company developing siRNA treatments for neurological diseases. Comparable as a next-generation RNAi player focused on previously intractable CNS targets, similar to Tallas's undruggable-target positioning.
• ProQR Therapeutics: Clinical-stage RNA therapeutics company developing Axiomer RNA editing technology for rare diseases. Comparable in modality class (RNA-based editing/therapeutics) and disease focus (rare genetic conditions) to Tallas's RNAi approach.
• Wave Life Sciences: Clinical-stage RNA therapeutics company using PRISM platform for stereopure oligonucleotides. Adjacent peer that also targets genetic diseases including rare disorders, comparable in modality class but distinct chemistry (AIMer-based knockdown vs siRNA).
• Korro Bio: Clinical-stage RNA editing company using OPERA platform for adenosine deamination-based RNA editing. Comparable as a platform-based RNA therapeutics company pursuing genetic-disease targets via an RNA-mediated mechanism.
• Sirnaomics: Clinical-stage RNAi therapeutics company developing siRNA candidates for oncology and fibrosis. Comparable in stage (early clinical), modality (siRNA), and therapeutic focus to Tallas's pipeline approach.

Direct peers

• Dicerna Pharmaceuticals (Novo Nordisk): Was a leading RNAi therapeutics developer (acquired by Novo Nordisk in 2021) using GalNAc-conjugated siRNA technology. Directly comparable mechanism and target disease areas to Tallas, illustrating the acquisition exit path that Tallas's GTM strategy implies.
• Arrowhead Pharmaceuticals: Clinical-stage RNAi therapeutics company with a broad pipeline across rare diseases, oncology, and hepatitis B using proprietary TRiM™ platform. Highly comparable to Tallas in targeting mechanism (RNAi gene silencing) and disease areas (rare disease + oncology) but with multiple Phase 2/3 assets and major pharma partnerships.

Broad incumbents

• Ionis Pharmaceuticals: Pioneer in antisense oligonucleotide (ASO) therapeutics with multiple approved drugs (Spinraza, Tegsedi, etc.). Comparable as an RNA-targeting therapeutics company addressing rare diseases and oncology, though Ionis uses ASO chemistry rather than siRNA.
• Alnylam Pharmaceuticals: The market-leading RNAi therapeutics company with multiple approved siRNA products (Onpattro, Givlaari, etc.) and a deep clinical pipeline. Directly comparable to Tallas as both develop RNAi-based drugs via the same RISC-mediated mechanism, but Alnylam operates at vastly larger scale with established commercialization.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat2 records

Key risks6 records

Key highlights5 records

Customer concentration

• Xx.com/tallasbio
• Facebookfacebook.com/TallasBiotech
• LinkedInlinkedin.com/company/tallas

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Tallas Biotech Inc.